 CRANBURY, N.J., June 29, 2021 PRNewswire -- Palatin Technologies, Inc. Palatin NYSE American: PTN a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin peptide receptor system, today announced the completion of an End-of-Phase 2 EOP2 meeting with the U.S. Food and Drug Administration FDA for PL9643 for the treatment of dry eye disease DED. 